Elez et al1 recently showed the novel potential of RNF43 mutations to predict clinical benefit and favorable outcomes in patients with metastatic microsatellite stable (MSS) colorectal cancer (mCRC) and BRAFV600E mutated treated with anti-EGFR/BRAF combinatory regimens. The gene discussed is BRAF; the disease is colorectal cancer.